Login / Signup

Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: scandinavian cohort study.

Arvid EngströmJonas SöderlingAnders HviidBjörn EliassonSoffia GudbjörnsdottirViktor WintzellKristian HveemChristian JonassonMads MelbyeBjörn PasternakPeter Ueda
Published in: European heart journal. Cardiovascular pharmacotherapy (2024)
Use of empagliflozin and dapagliflozin was associated with similar risk of cardiovascular and renal outcomes, mortality and diabetic ketoacidosis.
Keyphrases
  • randomized controlled trial
  • type diabetes
  • systematic review
  • cardiovascular events
  • risk factors
  • cardiovascular disease
  • metabolic syndrome
  • insulin resistance